Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...
TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...
Would-be dads taking drugs to stop their epilepsy seizures—and valproate in particular—should be largely reassured that the available evidence on the developmental risks to their offspring doesn’t ...
Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...
Novartis is just months away from filing ... in phase 3 trials for chronic inducible urticaria (CINDU) and multiple sclerosis (MS), and in phase 2 for hidradenitis suppurativa (HS) and food ...
Medpage Today on MSN1d
Women With MS Less Likely to Receive Treatment Than MenWomen were less likely than men to be treated for relapsing multiple sclerosis (MS), French registry data showed. Women had a ...
Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these ...
Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience, Including Successful Launches ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback